DXNVX, Consecutive Quarterly Profits... "Record-Breaking Performance Expected This Year"

[Asia Economy Reporter Jang Hyowon] DxVx announced on the 17th that it recorded consolidated sales of 13 billion KRW and operating profit of 1.1 billion KRW in the first half of this year, shedding its past image as a deficit company and reborn as a new enterprise.

DxVx significantly exceeded last year's annual sales of 7.4 billion KRW in the first half and continued operating profit for two consecutive quarters following the first quarter, marking completely transformed results within half a year since the new management team joined. As the performance improvement trend continues, it is expected to achieve the highest record ever this year.

The bio healthcare sector, promoted as a new business by DxVx, led the performance growth, and along with the restructuring of existing business divisions and the synergy effect with the global network of its affiliate, Kori Group, steady growth is expected in the second half as well.

In particular, infant healthcare products planned and developed by the DxVx Microbiome Research Institute are being sold successfully as premium products at over 12,000 infant product specialty stores and online in China. With continuous additions to the new product lineup and expansion of distribution channels through partnerships with domestic and international companies, growth in the bio healthcare sector is expected to continue.

Currently, DxVx is also sparing no investment in next-generation technology research and new product development. It has been selected for a government national project to build an “AI-based augmented mRNA vaccine platform” in collaboration with Hanyang University and is conducting research. Additionally, it is collaborating with Kori Group on “immune cell profiling research” for next-generation vaccine development and working with leading domestic and international research institutions to advance technology research and commercialization.

In the second half of the year, the company plans to expand services through CRAM (Contract Research and Manufacturing) by combining its genome-based technology with GMP-standard contract development and manufacturing organization (CDMO). With the advent of the endemic era and increased awareness of the importance of daily quarantine, it plans to continue performance growth by launching daily quarantine products based on postbiotics antimicrobial substances.

Park Sangtae, CEO of DxVx, stated, “Having exceeded last year’s annual sales in the first half and entering a full-fledged performance growth phase, we expect this year’s annual results to record the highest ever since our founding. Based on profitability and business sustainability, we will leap forward as a bio healthcare company providing personalized total solutions through organic integration of each business area.”

This content was produced with the assistance of AI translation services.